About Valentina Nardi, MD

Dr. Nardi is an assistant professor of pathology at Harvard Medical School and a hematopathologist and molecular genetic pathologist at the Massachusetts General Hospital in Boston. She received her M.D. from the University of Genoa, Italy where she completed an internship followed by a fellowship in hematology/oncology. Dr. Nardi joined George Daley’s laboratory at Boston Children’s Hospital as a postdoctoral fellow studying resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. This research led to her decision to pursue molecular diagnostics as a career. After the postdoctoral fellowship, Dr. Nardi enrolled in the anatomic pathology residency program at the Massachusetts General Hospital where she also completed a fellowship in hematopathology. After a second fellowship in Molecular Genetic Pathology at the Brigham and Women’s Hospital Dr. Nardi joined the faculty at Massachusetts General Hospital, Department of Pathology and Center for Integrated Diagnostics (CID) where she focuses on implementing molecular assays for hematological malignancies with a research interest in rapid detection of known and novel gene fusions in leukemias and sarcomas.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, University of Genoa Medical School
  • Residency, Massachusetts General Hospital
  • Fellowship, Boston Children's Hospital
  • Fellowship, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital
  • Fellowship, University of Genova

American Board Certifications

  • Anatomic Pathology, American Board of Pathology
  • Hematopathology, American Board of Pathology
  • Molecular Genetic Pathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Nardi???s research is focused on molecular characterization of rare solid tumors and of myeloid neoplasms, in an effort to uncover underlying genetic driver mutations amenable to therapeutic intervention or responsible for acquired resistance to therapy. Dr. Nardi's research interests include

  • Resistance to targeted therapeutics
  • Genetic alterations in hematological malignancies and solid tumors
  • Novel diagnostic and prognostic markers in hematological malignancies and solid tumors
  • Development and implementation of molecular assays

For more information about research concepts and co-authors visit  Dr. Nardi's profile at the Harvard Clinical and Translational Science Center.


Reviews: Comments and Ratings